Aruna Chakrala
Adolescent Medicine · Plainsboro, NJNPI 1447366539
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Lilly USA, LLC at 24.4% of the total. Reporting peaked in 2022 at $647 and has fallen 72.3% since, to $179 in 2025.
Across 137 payments — averaging $12.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$430
- Novo Nordisk$420
- Boehringer Ingelheim$243
- AstraZeneca$240
- Arbor Pharmaceuticals, Inc.$112
- Abbott$79
- plus $238 from 7 others
What the payments were for
- Food & beverage$1,74199%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 33 | $430 |
| Novo Nordisk | 41 | $420 |
| Boehringer Ingelheim | 19 | $243 |
| AstraZeneca | 12 | $240 |
| Arbor Pharmaceuticals, Inc. | 10 | $112 |
| Abbott | 5 | $79 |
| Amgen | 6 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $40 |
| Exact Sciences | 2 | $34 |
| Pfizer | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Astellas Pharma US Inc | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$1,762 in reported general payments places this provider in the 85th percentile of 156 adolescent medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 135 | $167,413 |
| OzempicSemaglutide | 69 | $98,911 |
| FarxigaDapagliflozin Propanediol | 32 | $39,345 |
| JanuviaSitagliptin Phosphate | 34 | $38,250 |
| RybelsusSemaglutide | 28 | $38,084 |
| JanumetSitagliptin Phos/Metformin Hcl | 42 | $35,878 |
| LinzessLinaclotide | 31 | $31,208 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 38 | $27,844 |
| JentaduetoLinagliptin/Metformin Hcl | 13 | $11,804 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $11,399 |
| TradjentaLinagliptin | 12 | $8,971 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $8,089 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,215 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 31 | $2,607 |
| Rosuvastatin Calcium | 182 | $1,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $430 | $167,413135 claims |
| Novo NordiskOzempic, Rybelsus | $420 | $136,99697 claims |
| Boehringer IngelheimTrijardy Xr, Jentadueto, Tradjenta | $243 | $48,61963 claims |
| AstraZenecaFarxiga, Symbicort | $240 | $44,56045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 adolescent medicine providers in New Jersey.
Other adolescent medicine in Plainsboro
- Manamadurai SomasundaramPlainsboro$352
- Silvio QuagliaMillburn$101K
- Randy TalamayanLakewood$15K
- Thomas PitosciaMillburn$11K
- Susan Brill-GoldbergNew Brunswick$7K
- Amita PatelElizabeth$7K
- Robert JohnsonNewark$6K
- Richard ReutterLong Branch$6K
- Anil KhandelwalPlainfield$5K
- John CavutoWestfield$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.